MAPT and Alzheimer disease: In the search for reliable biomarkers in AD, great attention has focused on Aβ and tau measurement in cerebrospinal fluid (CSF) and blood, together with neuroimaging techniques looking at glucose metabolism (FDG-PET), amyloid deposition (Pittsburgh compound B-PET and derivatives) and hippocampal volume measurement on MRI (Jack and Holtzman, 2013; Femminella and Edison, 2014).